» Articles » PMID: 35488255

Risk Factors of White Matter Hyperintensities in Migraine Patients

Overview
Journal BMC Neurol
Publisher Biomed Central
Specialty Neurology
Date 2022 Apr 29
PMID 35488255
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Migraine frequently is associated with White Matter Hyperintensities (WMHs). We aimed to assess the frequency of WMHs in migraine and to assess their risk factors.

Methods: This is cross-sectional study included 60 migraine patients of both genders, aged between 18 and 55 years. Patients with vascular risk factors were excluded. We also included a matched healthy control group with no migraine. Demographic, clinical data, and serum level of homocysteine were recorded. All subjects underwent brain MRI (3 Tesla).

Results: The mean age was 38.65 years and most of our cohort were female (83.3). A total of 24 migraine patients (40%) had WMHs versus (10%) in the control group, (P < 0.013). Patients with WMHs were significantly older (43.50 + 8.71 versus. 35.92+ 8.55 years, P < 0.001), have a longer disease duration (14.54+ 7.76versus 8.58+ 6.89 years, P < 0.002), higher monthly migraine attacks (9.27+ 4. 31 versus 7.78 + 2.41 P < 0.020) and high serum homocysteine level (11.05+ 5.63 versus 6.36 + 6.27, P < 0.006) compared to those without WMHs. WMHs were more frequent in chronic migraine compared to episodic migraine (75% versus 34.6%; P < 0.030) and migraine with aura compared to those without aura (38.3% versus 29,2; P < 0.001). WMHs were mostly situated in the frontal lobes (83.4%), both hemispheres (70.8%), and mainly subcortically (83.3%).

Conclusion: Older age, longer disease duration, frequent attacks, and high serum homocysteine level are main the risk factors for WMHs in this cohort. The severity or duration of migraine attacks did not increase the frequency of WMHs. The number of WMHs was significantly higher in chronic compared to episodic migraineurs.

Citing Articles

Plasma levels of glial fibrillary acidic protein and neurofilament light chain in patients with chronic migraine: a multicenter case-control study.

Colombo E, Doretti A, Rao R, Verde F, Sodano M, De Gobbi A Neurol Sci. 2025; .

PMID: 39856378 DOI: 10.1007/s10072-025-08011-2.


Association of White Matter Hyperintensities With Serum Lipid Profile and Hematologic Parameters in Migraine Patients.

Ucan Tokuc F, Ocal R Cureus. 2024; 16(9):e70452.

PMID: 39473650 PMC: 11521356. DOI: 10.7759/cureus.70452.


Prevalence and clinical characteristics of white matter hyperintensities in Migraine: A meta-analysis.

Zhang W, Cheng Z, Fu F, Zhan Z Neuroimage Clin. 2023; 37:103312.

PMID: 36610309 PMC: 9827384. DOI: 10.1016/j.nicl.2023.103312.

References
1.
Colombo B, Dalla Libera D, Comi G . Brain white matter lesions in migraine: what's the meaning?. Neurol Sci. 2011; 32 Suppl 1:S37-40. DOI: 10.1007/s10072-011-0530-7. View

2.
. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002; 288(16):2015-22. DOI: 10.1001/jama.288.16.2015. View

3.
Chen Z, Chen X, Liu M, Liu S, Ma L, Yu S . Disrupted functional connectivity of periaqueductal gray subregions in episodic migraine. J Headache Pain. 2017; 18(1):36. PMC: 5359195. DOI: 10.1186/s10194-017-0747-9. View

4.
Seneviratne U, Chong W, Billimoria P . Brain white matter hyperintensities in migraine: clinical and radiological correlates. Clin Neurol Neurosurg. 2012; 115(7):1040-3. DOI: 10.1016/j.clineuro.2012.10.033. View

5.
Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H . Cortical spreading depression activates and upregulates MMP-9. J Clin Invest. 2004; 113(10):1447-55. PMC: 406541. DOI: 10.1172/JCI21227. View